Healthcare
UAE scientists harness AI to discover potential blood-cancer drug
UAE researchers at Insilico Medicine used AI to identify potential PROTAC drugs for blood cancers. The approach combines AI-based target discovery with molecular design and may shorten early drug-selection timelines.
Researchers at Insilico Medicine used artificial-intelligence platforms to identify a new class of PROTAC molecules intended to target proteins associated with blood cancers, including certain leukaemias and lymphomas. The work was conducted by scientists based in Masdar City, Abu Dhabi, making it a UAE-based healthcare and drug-discovery development.
The company’s PandaOmics platform helped identify disease-related protein targets. Its Chemistry42 platform was then used to design molecules with a shape capable of binding to the selected target.
The reported approach is significant because it applies AI to both target discovery and molecular design rather than using computational tools only for screening existing compounds. Insilico said the method can reduce drug-selection timelines to approximately 12 to 18 months, compared with roughly two-and-a-half to four years for traditional approaches.
The compounds remain potential drug candidates rather than approved treatments. Their importance lies in demonstrating how Abu Dhabi-based research infrastructure and AI-enabled biotechnology are being used to accelerate early-stage oncology research.
Original source: The National